• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发灶不明的癌症:影像学、病理学和分子生物学结果不一致时的情况

Cancer of Unknown Primary: When Imaging, Pathology, and Molecular Biology Do Not Match.

作者信息

Juarez-Vignon Whaley Juan Jose, Pophali Prateek, Chornenkyy Yevgen, Linton Peters Mary

机构信息

Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

出版信息

Case Rep Oncol. 2024 Jun 27;17(1):695-704. doi: 10.1159/000539650. eCollection 2024 Jan-Dec.

DOI:10.1159/000539650
PMID:39015643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11249445/
Abstract

INTRODUCTION

Cancers of unknown primary are aggressive and rare malignancies with a complex diagnosis and management. Here we present a case in which imaging, pathology, and molecular biology did not match for a specific tumor site and the importance of a multidisciplinary team for these complicated cases.

CASE PRESENTATION

A man in his 70s with strong smoking history under workup for suspicion of metastatic lung cancer underwent lung mass biopsy. Immunohistochemical stains corresponded to hepatocellular/cholangiocarcinoma or germ cell tumor; however, dedicated liver and testicular studies including imaging and iscochrome 12p FISH were negative. Additionally, somatic variant profiling was not specific for any malignancy nor targetable variants. Given the pattern of disease, risk factors, and patient history, the patient received treatment for lung adenocarcinoma (carboplatin, pemetrexed, and pembrolizumab). The patient had a drastic improvement in dyspnea, weight gain, and was able to return to work.

CONCLUSION

This report describes a case in which immunohistochemistry and molecular profiling did not identify the tissue of origin and highlights the importance of a multidisciplinary team to reach a diagnosis and guide treatment without delaying patient care in patients with these diagnoses.

摘要

引言

原发灶不明的癌症是侵袭性的罕见恶性肿瘤,其诊断和管理复杂。在此,我们报告一例病例,其中影像学、病理学和分子生物学检查结果与特定肿瘤部位不匹配,强调了多学科团队对这些复杂病例的重要性。

病例介绍

一名70多岁有重度吸烟史的男性因疑似转移性肺癌接受检查,对肺部肿块进行了活检。免疫组化染色结果符合肝细胞癌/胆管癌或生殖细胞肿瘤;然而,包括影像学检查和12号染色体短臂荧光原位杂交(FISH)在内的专门肝脏和睾丸检查均为阴性。此外,体细胞变异分析未发现任何特定恶性肿瘤或可靶向变异。鉴于疾病模式、危险因素和患者病史,患者接受了肺腺癌治疗(卡铂、培美曲塞和帕博利珠单抗)。患者呼吸困难明显改善,体重增加,能够重返工作岗位。

结论

本报告描述了一例免疫组化和分子分析未能确定组织来源的病例,并强调了多学科团队在这些诊断患者中进行诊断和指导治疗而不延误患者护理的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c820/11249445/0b0ffd2b4f84/cro-2024-0017-0001-539650_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c820/11249445/4754c3d5368d/cro-2024-0017-0001-539650_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c820/11249445/0b0ffd2b4f84/cro-2024-0017-0001-539650_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c820/11249445/4754c3d5368d/cro-2024-0017-0001-539650_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c820/11249445/0b0ffd2b4f84/cro-2024-0017-0001-539650_F02.jpg

相似文献

1
Cancer of Unknown Primary: When Imaging, Pathology, and Molecular Biology Do Not Match.原发灶不明的癌症:影像学、病理学和分子生物学结果不一致时的情况
Case Rep Oncol. 2024 Jun 27;17(1):695-704. doi: 10.1159/000539650. eCollection 2024 Jan-Dec.
2
The decisive role of molecular pathology in presumed somatic metastases of type II testicular germ cell tumors: report of 2 cases.分子病理学在 II 型睾丸生殖细胞肿瘤疑似体瘤转移中的决定性作用:2 例报告。
Diagn Pathol. 2020 Jul 25;15(1):99. doi: 10.1186/s13000-020-01011-0.
3
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.专家共识:晚期或转移性上皮性卵巢癌的评估和管理。
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.
4
Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.基于基因表达谱的免疫化学疗法实现转移性未知原发腺癌的完全缓解:病例报告及文献复习。
Front Immunol. 2023 Apr 19;14:1181444. doi: 10.3389/fimmu.2023.1181444. eCollection 2023.
5
Case report: Salivary duct carcinoma in a patient with a germline pathogenic variant - expanding the spectrum of hereditary cancer predisposition syndromes.病例报告:一名携带胚系致病变异的患者发生涎腺导管癌——扩大遗传性癌症易感性综合征的范围
Front Oncol. 2024 Apr 8;14:1372382. doi: 10.3389/fonc.2024.1372382. eCollection 2024.
6
Brain Metastases as Presenting Feature in 'Burned Out' Testicular Germ Cell Tumor.脑转移作为“消退型”睾丸生殖细胞肿瘤的首发特征
Cureus. 2016 Apr 1;8(4):e551. doi: 10.7759/cureus.551.
7
Molecular genetic evidence supporting the origin of somatic-type malignancy and teratoma from the same progenitor cell.支持体瘤样恶性肿瘤和畸胎瘤起源于同一祖细胞的分子遗传学证据。
Am J Surg Pathol. 2012 Dec;36(12):1849-56. doi: 10.1097/PAS.0b013e31826df1ab.
8
A Rare Case of Metachronous Quadruple Primary Malignancies in a Single Patient: A Case Report and Comprehensive Literature Review.一名患者发生异时性四重原发性恶性肿瘤的罕见病例:病例报告及文献综述
Cureus. 2022 May 27;14(5):e25405. doi: 10.7759/cureus.25405. eCollection 2022 May.
9
A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.多学科方法治疗复发性转移性胸腺癌的独特病例:病例报告
Ther Adv Rare Dis. 2023 Aug 11;4:26330040231190661. doi: 10.1177/26330040231190661. eCollection 2023 Jan-Dec.
10
Clinical Practice Guideline: Evaluation of the Neck Mass in Adults.临床实践指南:成人颈部肿块的评估
Otolaryngol Head Neck Surg. 2017 Sep;157(2_suppl):S1-S30. doi: 10.1177/0194599817722550.

本文引用的文献

1
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.原发灶不明癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Mar;34(3):228-246. doi: 10.1016/j.annonc.2022.11.013. Epub 2022 Dec 20.
2
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.原发不明癌中拷贝数改变和肿瘤突变负担的预后影响。
Genes Chromosomes Cancer. 2022 Sep;61(9):551-560. doi: 10.1002/gcc.23047. Epub 2022 Apr 30.
3
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.
开放标签 II 期研究纳武利尤单抗治疗不明原发癌的疗效。
Ann Oncol. 2022 Feb;33(2):216-226. doi: 10.1016/j.annonc.2021.11.009. Epub 2021 Nov 26.
4
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.原发灶不明癌患者生存个体化预测的新型列线图的建立与验证
Clin Cancer Res. 2021 Jun 15;27(12):3414-3421. doi: 10.1158/1078-0432.CCR-20-4117. Epub 2021 Apr 15.
5
Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing.应用荧光原位杂交、单核苷酸多态性微阵列和下一代测序/配对测序技术评估生殖细胞肿瘤中的 12p 等臂染色体和 12p 异常。
Hum Pathol. 2021 Jun;112:20-34. doi: 10.1016/j.humpath.2021.03.008. Epub 2021 Mar 31.
6
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.整合临床与分子特征鉴定出 RAS 激活和 CDKN2A 缺失是不明原发癌的独立不良预后因素。
Int J Cancer. 2020 Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11.
7
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.随机Ⅱ期临床试验比较基于基因表达谱的肿瘤未知原发灶患者个体化治疗与卡铂联合紫杉醇的疗效
J Clin Oncol. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771. Epub 2019 Jan 17.
8
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.原发部位不明的癌症:精准医学时代的新治疗模式
Am Soc Clin Oncol Educ Book. 2018 May 23;38:20-25. doi: 10.1200/EDBK_100014.
9
Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.不明原发癌-流行病学趋势和全面基因组分析的相关性。
Cancer Med. 2018 Sep;7(9):4814-4824. doi: 10.1002/cam4.1689. Epub 2018 Jul 17.
10
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.针对免疫检查点阻断治疗反应的生物标志物,对不明原发癌进行全面分析。
Eur J Cancer. 2018 May;94:179-186. doi: 10.1016/j.ejca.2018.02.021. Epub 2018 Mar 20.